HK inno.N’s novel drug “K-CAB” officially enters the Indian GERD treatment market
HK inno.N’s novel drug “K-CAB” officially enters the Indian GERD treatment market Launched under the brand name ‘PCAB’ in India, the world’s most populous country Local sales and marketing to be managed by Dr. Reddy’s Laboratories Korea’s novel drug “K-CAB” strengthening its global presence in top overseas GERD treatment markets
Photo: Product image of PCAB launched in India (Korean product name: K-CAB)
HK inno.N announced on the 17th that it officially launched “K-CAB (active ingredient: tegoprazan),” its novel treatment for gastroesophageal reflux disease (GERD), in India, with Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, managing local sales and marketing. K-CAB received regulatory approval in India last May under the brand name ‘PCAB 50mg’ for the treatment of erosive GERD, non-erosive GERD, and gastric ulcers. In 2022, HK inno.N signed a contract with Dr. Reddy’s Laboratories Ltd. to export finished K-CAB tablets to India and six other emerging markets. As of 2024, India is the peptic ulcer treatment market ranking fourth globally at a value of approximately KRW 1.52 trillion, following China, the U.S., and Japan. Approximately 38% of the Indian population is estimated to suffer from GERD, and effective management of the condition is considered increasingly important. Dr. Reddy’s Laboratories plans to introduce K-CAB (Indian brand name: PCAB) 50mg to the local market this month, thus aiming to pioneer a new paradigm in the Indian GERD treatment market. “The launch of PCAB is the fruition of our dedication to bringing forward innovative treatment options in the field of GERD,” commented M.V. Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr. Reddy’s Laboratories. “Dr. Reddy’s Laboratories has established a strong and trusted position in this field by building up a broad range of product portfolios, involving Omez® (omeprazole), Razo® (rabeprazole), and Vono™ (vonoprazan). By enhancing partnership synergy with HK inno.N, we will be committed to supplying novel drugs that could bridge the gap in GERD management and improve patient access.” “We are very excited to see K-CAB reaching India, one of global top pharmaceutical markets,” Kwak Dal-won, CEO of HK inno.N said, adding, “As introduced under the Indian brand name ‘PCAB,’ we have high expectations of success in its presence as a global first-in-class novel drug in the P-CAB category, offering a novel therapeutic opportunity for Indian patients.” K-CAB, Korea’s 30th novel drug, achieved cumulative domestic prescription sales worth KRW 810.1 billion since its launch in March 2019, projected to reach this figure by the first half of 2025. With △ rapid action after administration, △ safety demonstrated even after long-term use for up to six months, etc., K-CAB has ranked No. 1 in domestic outpatient prescription sales for peptic ulcer treatment. Currently, HK inno.N has entered into agreements for the export of technology or finished products to 53 countries and has expanded its global presence, with K-CAB launched in 18 countries including South Korea, China, and several Latin American nations. (The End)